small nuclear ribonucleoprotein polypeptide C pseudogene 16Genealiases: []
Q-omics provides the consensus-scored SNRPCP16 profile across patient tissues and cancer cell-line models. SNRPCP16 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, SNRPCP16 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, SNRPCP16 RNA expression shows 11,903 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRP, and THYM as cancer lineages where SNRPCP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP16 survival associations across molecular data types. SNRPCP16 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP16 RNA expression–survival associations across cancer types. High SNRPCP16 expression shows unfavorable associations in STAD, but favorable associations in BRCA, LAML, SKCM, CESC and ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for SNRPCP16 RNA expression.
This table summarizes SNRPCP16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP16 shows lower tumor expression in KIRP, KICH, THCA, BRCA and UCEC. The KIRP box plot shows higher SNRPCP16 RNA expression in normal versus tumor tissue (log2 FC = −0.667, t-test p = .004).
This table shows molecular features associated with SNRPCP16 in patient tissues and cancer cell lines. In patient samples, SNRPCP16 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
